Abatacept

Evidence Level: L3 Predicted Indications: 7

Table of Contents

  1. Abatacept
    1. Pharmacist Assessment Report
    2. Abatacept: selective T-cell co-stimulation modulator → ankylosing spondylitis
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. Australia Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Abatacept: selective T-cell co-stimulation modulator → ankylosing spondylitis

One-Sentence Summary

Abatacept is a CTLA4-Ig fusion protein that blocks T-cell co-stimulation (CD28–CD80/86), and it is marketed in Australia as an injectable biologic. The TxGNN model predicts it may be effective for ankylosing spondylitis. Support is limited: 1 disease-specific Phase 2 open-label pilot trial and 1 open-label pilot publication, alongside reviews noting that T-cell-targeted biologics have not been effective in this disease.

Quick Overview

Item Content
Original Indication Not recorded in the local data
Predicted New Indication ankylosing spondylitis
TxGNN Prediction Score 0.9991
Evidence Level L3
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)
Recommended Decision Hold

Why is This Prediction Reasonable?

Abatacept blocks the CD28–CD80/86 co-stimulation pathway, reducing T-cell activation. T-cell-driven inflammation is implicated in spondyloarthritis, so the mechanism is plausible in principle. Detailed mechanism-of-action data were not available in the data compiled for this report, so this reasoning relies on the known class biology of CTLA4-Ig.

There are important caveats. In ankylosing spondylitis, the TNF and IL-17 pathways are the dominant therapeutic targets. One review in the data (Sieper, 2016) states that non-TNF biologics targeting IL-1, IL-6 and T cells (abatacept) are not effective in axial spondyloarthritis. Another describes abatacept as an option “beyond TNF blockade” rather than a proven treatment. The prediction is therefore mechanistically plausible but contested by the available clinical commentary.

Clinical Trial Evidence

Trial Number Phase Status Enrolment Key Findings
NCT00558506 Phase 2 Unknown 30 Open-label, single-arm pilot of intravenous abatacept in ankylosing spondylitis, up to week 30. No control arm; preliminary signal only.
NCT01965132 N/A Recruiting 10000 Korean registry of biologics and targeted DMARDs in RA, AS and PsA. Observational, real-world safety context only.
NCT07138898 Phase 2 Recruiting 80 Perioperative immunosuppressant management in rheumatology patients having shoulder arthroplasty. Does not test abatacept efficacy in AS.

Literature Evidence

PMID Year Type Journal Key Findings
21415053 2011 Open-label pilot study Ann Rheum Dis 24-week pilot exploring short-term efficacy and safety of abatacept in active ankylosing spondylitis.
27856659 2016 Review Rheumatology (Oxford) TNF blockers are highly effective in axial SpA; non-TNF biologics including abatacept are described as not effective.
25488787 2014 Review Best Pract Res Clin Rheumatol Treatment of spondyloarthritis beyond TNF-alpha blockade.
31171316 2018 Review Best Pract Res Clin Rheumatol Emerging options in spondyloarthritis, including IL-17A inhibition for patients not responding to NSAIDs.
21624184 2011 Review Arthritis Res Ther New targeted therapeutics across RA, AS and PsA.
18251219 2008 Review Rev Med Suisse Highlights in rheumatology 2007, including abatacept’s mode of action.
29278210 2017 Review Curr Pharm Biotechnol Biologics in inflammatory arthritis, including spondyloarthritis.
31852268 2020 Review Expert Rev Clin Immunol Infection risk with biologic versus non-biologic therapy in inflammatory arthritis.

Australia Market Information

ARTG Number Product Name Dosage Form Approved Indication
ARTG 11684Y Orencia ClickJect Injection 125 mg in 1 mL single dose autoinjector Not recorded in the local data

Safety Considerations

  • Drug Interactions: 73 interactions were recorded. Major-level interactions include adalimumab, baricitinib, certolizumab pegol and live BCG vaccine. Moderate-level interactions include other immunosuppressive or biologic agents (e.g. anakinra, alemtuzumab, azathioprine, canakinumab) and several live or attenuated vaccines. Minor-level interactions include zinc salts.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The only disease-specific data are two small, uncontrolled pilot studies, and published reviews describe abatacept as not effective in axial spondyloarthritis. The high TxGNN score alone does not outweigh this.

To proceed, the following is needed:

  • Results of the open-label pilot trials (NCT00558506 has unknown status) and any controlled data in ankylosing spondylitis
  • Detailed mechanism-of-action data
  • Review of the TGA Product Information for warnings and contraindications
  • A concurrent-biologic safety plan, given the major interactions with TNF inhibitors and JAK inhibitors

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.